Financial News

Recent Quotes

My Watchlist

Indicators

Overview

Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy

By: TalkMarkets

September 16, 2023 at 13:59 PM EDT

Hasten Biopharma entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Meanwhile, Insilico Medicine out-licensed global rights to a small molecule inhibitor of USP1 for BRCA-mutated tumors to Exelixis.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Financial News

Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy

Popular Pages